Covidh Technologies Limited announced significant corporate restructuring decisions following its board meeting held on March 10, 2026. The company formally communicated these decisions to BSE Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Corporate Identity and Office Changes

The board approved a proposal to change the company name from "Covidh Technologies Limited" to "iSERALifesciences Limited." The company has obtained approval for name reservation from the Ministry of Corporate Affairs (MCA). This change requires alteration of the Memorandum of Association and Articles of Association, subject to shareholder approval through special resolution.

Simultaneously, the board approved shifting the registered office within Pune from "Office No. 4, Kumar Prestige Point, 238 Shukrawar Peth, Pune City, Maharashtra – 411002" to "Office No. A1-1202, 12th Floor, Boulevard Tower, Phase-2, CTS No. 11, Sadhu Vaswani Chowk, Camp, Pune – 411001, Maharashtra," effective April 1, 2026.

Executive Director Appointments

Based on recommendations from the Nomination and Remuneration Committee, the board approved two executive director appointments for 5-year terms:

Non-Executive Director Appointments

The board also recommended two non-executive director appointments for 5-year terms:

Shareholder Approval Process

The board approved the Notice of Extraordinary General Meeting (EGM) scheduled for Thursday, April 2, 2026 at 12:00 P.M. through Video Conferencing. All proposed changes including the name change and director appointments require shareholder approval at this EGM.

The board meeting commenced at 02:00 P.M. and concluded at 03:15 P.M. on March 10, 2026. The EGM notice will be dispatched to stock exchanges and members, and made available on the company website and BSE Limited's website.

Covidh Technologies Limited has issued a revised disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, correcting an inadvertent error in the target entity name for its proposed acquisition announced on February 23, 2026.

Correction of Target Entity Name

The company clarified that the target entity name was incorrectly mentioned as "iSERA Biological Private Limited" in the original disclosure. The correct name of the target entity is "iSERA Biological Limited." This correction was made to ensure accuracy in regulatory filings and public disclosures.

Transaction Structure Remains Unchanged

The proposed acquisition structure and terms remain identical to the original disclosure. Covidh Technologies Limited will acquire 100% equity shareholding of iSERA Biological Limited through a non-binding Letter of Intent executed on February 23, 2026. Upon successful completion, iSERA Biological Limited will become a wholly owned subsidiary of the company.

Conditions and Regulatory Framework

The proposed acquisition continues to be subject to the same conditions precedent, including execution of definitive agreements, completion of satisfactory due diligence, receipt of necessary regulatory and statutory approvals, and obtaining shareholders' approvals. The non-binding Letter of Intent remains non-binding except for customary provisions relating to confidentiality, exclusivity, governing law, and costs.

Compliance and Future Disclosures

The revised disclosure emphasizes that all other contents of the earlier disclosure remain unchanged, with only the target entity name being corrected. The company reaffirmed its commitment to making further disclosures as required under SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, upon execution of definitive agreements and occurrence of material developments in the transaction process.